Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Lanraplenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1800046-95-0, Gs-syk, Lanraplenib [inn], Lanraplenib [usan], Lanraplenib (gs-9876), A6u64ou57e
    Molecular Formula
    C23H25N9O
    Molecular Weight
    443.5  g/mol
    InChI Key
    XCIGZBVOUQVIPI-UHFFFAOYSA-N
    FDA UNII
    A6U64OU57E
    Lanraplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon oral administration, lanraplenib binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine
    2.1.2 InChI
    InChI=1S/C23H25N9O/c24-21-12-25-11-19(28-21)20-13-32-6-5-26-23(32)22(29-20)27-16-1-3-17(4-2-16)30-7-9-31(10-8-30)18-14-33-15-18/h1-6,11-13,18H,7-10,14-15H2,(H2,24,28)(H,27,29)
    2.1.3 InChI Key
    XCIGZBVOUQVIPI-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N
    2.2 Other Identifiers
    2.2.1 UNII
    A6U64OU57E
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 1800046-95-0

    2. Gs-syk

    3. Lanraplenib [inn]

    4. Lanraplenib [usan]

    5. Lanraplenib (gs-9876)

    6. A6u64ou57e

    7. 6-(6-aminopyrazin-2-yl)-n-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine

    8. Gs-9876

    9. 6-(6-amino-2-pyrazinyl)-n-[4-[4-(3-oxetanyl)-1-piperazinyl]phenyl]-imidazo[1,2-a]

    10. 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

    11. 6-(6-amino-2-pyrazinyl)-n-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)imidazo(1,2-a)pyrazin-8-amine

    12. Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-n-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-

    13. 6-(6-aminopyrazin-2-yl)-n-{4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl}imidazo[1,2-a]pyrazin-8-amine

    14. Gs-syk?

    15. Lanraplenib (usan/inn)

    16. Lanraplenib [usan:inn]

    17. Unii-a6u64ou57e

    18. Lanraplenib [who-dd]

    19. Gtpl9764

    20. Chembl3986824

    21. Schembl16820581

    22. Example 2 [us9290505]

    23. Bdbm212271

    24. Bcp30292

    25. Ex-a3747

    26. Gs9876

    27. S9715

    28. Who 10601

    29. Db14770

    30. Gs-9876gs-9876

    31. Ex.-2, Us9290505

    32. Us9290505, Ex.-2

    33. Compound 39 [pmid: 32292557]

    34. Ac-36571

    35. Hy-109091

    36. Cs-0039383

    37. C92666

    38. D11596

    39. Gs-9876; Gs9876; Gs 9876

    40. 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazol[1,2-a]pyrazin-8-amine

    2.4 Create Date
    2016-02-23
    3 Chemical and Physical Properties
    Molecular Weight 443.5 g/mol
    Molecular Formula C23H25N9O
    XLogP31.4
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count9
    Rotatable Bond Count5
    Exact Mass443.21820645 g/mol
    Monoisotopic Mass443.21820645 g/mol
    Topological Polar Surface Area110 Ų
    Heavy Atom Count33
    Formal Charge0
    Complexity635
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1